Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Enterprise Value (2021 - 2025)

Historic Enterprise Value for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to -$892.4 million.

  • Immunocore Holdings' Enterprise Value rose 99.07% to -$892.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$892.4 million, marking a year-over-year increase of 99.07%. This contributed to the annual value of -$820.4 million for FY2024, which is 8534.29% down from last year.
  • Latest data reveals that Immunocore Holdings reported Enterprise Value of -$892.4 million as of Q3 2025, which was up 99.07% from -$882.8 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Enterprise Value peaked at -$321.1 million during Q4 2021, and registered a low of -$901.3 million during Q3 2024.
  • For the 5-year period, Immunocore Holdings' Enterprise Value averaged around -$617.0 million, with its median value being -$444.5 million (2023).
  • Per our database at Business Quant, Immunocore Holdings' Enterprise Value plummeted by 10339.52% in 2024 and then skyrocketed by 99.07% in 2025.
  • Over the past 5 years, Immunocore Holdings' Enterprise Value (Quarter) stood at -$321.1 million in 2021, then decreased by 25.32% to -$402.5 million in 2022, then dropped by 9.98% to -$442.6 million in 2023, then plummeted by 85.34% to -$820.4 million in 2024, then decreased by 8.77% to -$892.4 million in 2025.
  • Its Enterprise Value stands at -$892.4 million for Q3 2025, versus -$882.8 million for Q2 2025 and -$837.0 million for Q1 2025.